Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Capillary dysfunction is associated with symptom severity and neurodegeneration in Alzheimer's disease.

Nielsen RB, Egefjord L, Angleys H, Mouridsen K, Gejl M, Møller A, Brock B, Brændgaard H, Gottrup H, Rungby J, Eskildsen SF, Østergaard L.

Alzheimers Dement. 2017 Oct;13(10):1143-1153. doi: 10.1016/j.jalz.2017.02.007. Epub 2017 Mar 23.

PMID:
28343848
2.

In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.

Gejl M, Gjedde A, Egefjord L, Møller A, Hansen SB, Vang K, Rodell A, Brændgaard H, Gottrup H, Schacht A, Møller N, Brock B, Rungby J.

Front Aging Neurosci. 2016 May 24;8:108. doi: 10.3389/fnagi.2016.00108. eCollection 2016.

3.

Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain.

Gejl M, Lerche S, Egefjord L, Brock B, Møller N, Vang K, Rodell AB, Bibby BM, Holst JJ, Rungby J, Gjedde A.

Front Neuroenergetics. 2013 Mar 27;5:2. doi: 10.3389/fnene.2013.00002. eCollection 2013.

4.

Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.

Egefjord L, Gejl M, Møller A, Brændgaard H, Gottrup H, Antropova O, Møller N, Poulsen HE, Gjedde A, Brock B, Rungby J.

Dan Med J. 2012 Oct;59(10):A4519.

PMID:
23158895
5.

Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia.

Gejl M, Egefjord L, Lerche S, Vang K, Bibby BM, Holst JJ, Mengel A, Møller N, Rungby J, Brock B, Gjedde A.

J Cereb Blood Flow Metab. 2012 Dec;32(12):2146-52. doi: 10.1038/jcbfm.2012.118. Epub 2012 Aug 29.

6.

Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume.

Carmichael O, Xie J, Fletcher E, Singh B, DeCarli C; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2012 Jun;33(6):1124.e31-41. doi: 10.1016/j.neurobiolaging.2011.08.016. Epub 2011 Dec 14.

7.

Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.

Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J.

Expert Opin Ther Targets. 2011 Oct;15(10):1153-62. doi: 10.1517/14728222.2011.600691. Epub 2011 Jul 12. Review.

PMID:
21749267
8.

Using CSF biomarkers to replicate genetic associations in Alzheimer's disease.

Schott JM; ADNI Investigators.

Neurobiol Aging. 2012 Jul;33(7):1486.e9-15. doi: 10.1016/j.neurobiolaging.2011.02.008. Epub 2011 Apr 3.

9.

siRNA-mediated knock-down of ZnT3 and ZnT8 affects production and secretion of insulin and apoptosis in INS-1E cells.

Petersen AB, Smidt K, Magnusson NE, Moore F, Egefjord L, Rungby J.

APMIS. 2011 Feb;119(2):93-102. doi: 10.1111/j.1600-0463.2010.02698.x. Epub 2010 Dec 1.

PMID:
21208276
10.

Zinc, alpha cells and glucagon secretion.

Egefjord L, Petersen AB, Rungby J.

Curr Diabetes Rev. 2010 Jan;6(1):52-7. Review.

PMID:
20034370
11.

Zinc transporter gene expression is regulated by pro-inflammatory cytokines: a potential role for zinc transporters in beta-cell apoptosis?

Egefjord L, Jensen JL, Bang-Berthelsen CH, Petersen AB, Smidt K, Schmitz O, Karlsen AE, Pociot F, Chimienti F, Rungby J, Magnusson NE.

BMC Endocr Disord. 2009 Feb 25;9:7. doi: 10.1186/1472-6823-9-7.

Supplemental Content

Loading ...
Support Center